Plethysmographic and biochemical markers in the diagnosis of endothelial dysfunction in pediatric acute lymphoblastic leukemia survivors – new applications.

Aneta Masopustová[1], MD, Petr Jehlička[1], MD, PhD, Michal Huml[1], MD, PhD, TomášVotava[1], MD, PhD, LadislavTrefil[2], MSc, Marcela Kreslová[1], MD, Josef Sýkora[1], MD, PhD, Prof.

[1]Charles University in Prague, Faculty of Medicine in Pilsen, Faculty Hospital, Department of Paediatrics, Pilsen, the Czech Republic

[2]Charles University in Prague, Faculty of Medicine in Pilsen, Faculty Hospital, Department of Clinical Biochemistry and Haematology, Pilsen, the Czech Republic

Correspondence to:

AnetaMasopustová, MD, Charles University in Prague, Faculty of Medicine in Pilsen, Faculty Hospital, Department of Paediatrics, AlejSvobody 80, 304 00, Pilsen, The Czech Republic, tel.: + 420 377104337, Fax: + 420 377104694, e-mail: masopustovaa@fnplzen.cz

Short title:
Endothelial dysfunction in acute lymphoblastic leukemia

List of abbreviations

ADMA – asymmetric dimethyl arginine

ALL – acute lymphoblastic leukemia

ED – endothelial dysfunction

FMD – flow-mediated dilatation

HDL-C – high-density lipoproteins

hsCRP – high-sensitive C-reactive protein

IMT – intima-media thickness

LDL-C – low-density lipoproteins

NO – nitric oxide

PAT– peripheral arterial tone

RHI – reactive hyperemia index

TC – total cholesterol

TG – triglycerides

VCAM-1 – vascular cells adhesive molecule

Summary

Acute lymphoblastic leukemia (ALL) and its treatment are associated with endothelial dysfunction (ED) and increased cardiovascular risk in adulthood. There are no data on ED in children after successful treatment of ALL. We aimed to assess new ED in these children using the plethysmographic Reactive Hyperemia Index (RHI) and biomarkers that are known to be related to ED.

In all, 22 children (mean 15.6 yrs.), after successful treatment of ALL, and 18 healthy subjects were included in this prospective study. RHI, plasma concentrations of asymmetric dimethyl arginine (ADMA), high-sensitive CRP (hsCRP) and E-selectin were measured in all children.

RHI values were significantly lower in ALL patients when compared with healthy controls ($p < 0.05$). hsCRPwas significantly increased in ALL patients compared with the control group ($p < 0.001$). E-selectin plasma levels were higher in ALL patients as compared to healthy controls ($p = 0.05$).

This is the first study that combines both plethysmographic and biochemical methods to assess ED in ALL survivors. Significantly decreased RHI with elevated plasma concentrations of biochemical markers imply a possible association with premature ED in ALL patients. The combined diagnostic approach seems to be a valuable tool for more accurate detection of ED and preventive cardiovascular management in these patients.

Key words: endothelial dysfunction, reactive hyperemia index, E-selectin, acute lymphoblastic leukemia, children

Introduction

Acute lymphoblastic leukemia represents one fourth of all childhood malignancies (Gurney *et al.* 1995). The continuously improving cure rates of ALL exceed 85% nowadays (Horner *et al.* 2009). However, this success has comehand-in-hand with increasing numbers of late adverse effects (Silverman 2014) (Oeffinger *et al.* 2006). There is a growing population of pediatric ALL survivors at risk for developing late complications of their chemotherapy and radiotherapy given years or decades earlier (Bottomley and Kassner 2003) (De Caro *et al.*2011) (Leger *et al.* 2015)(Mody *et al.* 2008) (Kada-Lottick *et al.* 2010)(Bhatia 2003). Accordingly, extended life-long medical care for all survivors of ALL is warranted(Nathan *et al.* 2005) (Essig *et al.* 2014). Anhracycline-induced cardiotoxicity may lead to heart failure and dilated cardiomyopathy in children (Bryant *et al.* 2007). In this regard, anthracyclines may also induce changes in the vascular endothelium and could be a causative agent related to the pathogenesis of ED and premature atherosclerosis in young cancer survivors(Woo *et al.* 2013) (Jarvela *et al.* 2013)(Barry *et al.* 2007).

ED might be regarded as an integrated index of all atherogenic and atheroprotective factors present in an individual, including known, as well as yet-unknown, variables and genetic predispositions(Bonneti *et al.* 2003) (Morisson *et al.* 2010). Altered endothelial cell biology is thought to be part of the early pathogenesis of atherosclerosis, although the precise mechanism is yet to be discovered. The decreased bioactivity of nitric oxide (NO), leading to the promotion of vasoconstriction, inflammation and thrombosis, plays a crucial role in the pathogenesis of ED.From a clinical point of view, ED is characterized by reduced vasodilative responses to an appropriate ischemic stimulus(Hamburg *et al.* 2008).

The reversibility of ED may be an attractive primary target in the effort to optimizetherapeutic strategies and to decrease cardiovascular risk in pediatric ALL survivors. Early detection of this process may have therapeutic and prognostic implications (Widlanski *et al.* 2003). Unfortunately, ED has received little attention from researchers and studies on ED incidence in comparable pediatric ALL populations are lacking. Expanding on this, novel non-invasive diagnostic tools ensuring the capture of ED are needed(Bonneti *et al.* 2003).Based on these premises, the current study was conducted with the following specific aims: 1) to determine whether a significant difference in Reactive Hyperemia Index (RHI) is found in pediatric ALL survivors as compared to controls, 2) to discern if the association between RHI and specific biochemical markers in ALL survivors exists, and 3) to demonstrate whether the combination

of RHI and biochemical parameters can be used for the detection of ED in pediatric ALL survivors.

Materials and methods

The ALL group included 22 ALL survivors at least two years after successful cytostatic therapy. All of these subjectswere treated according to either BFM ALL 95 or ALL IC-BFM 2002 protocols. Neither patients with relapsed ALL nor with secondary ALL were enrolled in the study. All subjects had undergone a standard cardiology examination and all subjects had normal both systolic and diastolic heart function throughout the follow-up. Treatment protocols involved a combination of cytostatic drugs, including anthracycline chemotherapy agents (daunorubicine, doxorubicine) and cyclofosfamide. Cumulative doses of anthracyclines and cyclophosphamide were 240–360 mg/m^2 and 3000 mg/m^2, respectively.

In the control group, 18 healthy subjects without a history of inflammatory, metabolic or neoplastic diseases were enrolled. None of them reported a history of heart disease, treatment with antibiotics, anti-inflammatory drugs or medication with known adverse effects on the endothelial function. Demographic characteristics of the study sample are listed in Table 1. Exclusion criteria for both groups were dyslipidemia, positive family history of premature cardiovascular events, abnormal left-ventricular function, and smoking.

Methods

Reactive Hyperemia Index measurement

An EndoPAT® recorder (Itamar Caesarea®, Israel) was used for the determination of the RHI by measuring post-occlusive endothelium-dependent changes in vascular tone (PAT) in the subject´s fingertips. Initially, body mass index (BMI) and blood pressure in the non-dominant arm were measured. The subject was asked to rest in the supine position for 15 minutes in a temperature-controlled, quiet room with the unique biosensors placed on the fingertips. Then followed a five-minute brachial occlusion (60 mmHg above the systolic pressure, at least 200 mmHg). The post-occlusive dilatation with a reactive hyperemia was captured as an increase of the PAT signal amplitude. The RHI was calculated automatically thereafter. The contralateral arm was measured simultaneously to eliminate endothelium-independent changes in vascular tone.

Laboratory measurements

We obtained blood samples from all participating children in standard clinical settings after an overnight fasting. Specific biochemical markers of ED were: asymmetric dimethyl arginine (ADMA) as a competitive NO-synthase inhibitor, E-selectin and vascular cells adhesive molecules (VCAM-1) measured with Elisa (OLD Diagnostica®, BioVendor®), high-sensitive CRP (hsCRP) measured by a particle-enhanced immuno-turbidimetric assay technique (Orion Diagnostica®). All samples were collected by a qualified person and the tests were performed in a blinded fashion.

Statistics

Values obtained from individual measurements are expressed using descriptive statistics (mean, standard deviation, median, inter-quartile range). Statistical differences between healthy controls and patients with ALL were calculated using a sum rank test (Mann-Whitney test). All statistical analyses were performed usingSoftware SAS 9.4 (Cary, NC, USA) ®. For all analyses, a p-value of 0.05 or less was accepted as being statistically significant.

Ethical considerations

Our study was conducted in accordance with the principles of the Declaration of Helsinki. The local Ethics Committee approved the study protocol. An informed consent was obtained from the parents or legal guardians of all enrolled participant. The research was not sponsored by any company.

Results

Demographics of the study sample

A total of 40 children were eligible for inclusion. Refer to Table 1 for an overview of the baseline demographic and clinical characteristics of both the ALL survivors and the healthy controls (HC). Probands were of Caucasian ethnicity, comparable in regard to number ratio. There were no differences in lipid profile between the study groups.

RHI and biochemical parameters

RHI was significantly lower in the ALL patients as compared to HC: 1.5 (1.3; 2.0), 1.8 (1.59; 2.46), median and interquartile range, respectively; $p < 0.05$. (Figure 1)

hsCRP plasma levels were significantly higher in ALL patients as compared to HC: 1.1 (0.71; 2.29) mg/l; 0.19 (0.18; 0.45) mg/l; respectively; $p < 0.001$. (Figure 2)

E-selectin levels of the children with ALL were higher when compared to HC: 76.0 (58.32; 108.98) ug/l, 62.5 (31.66; 70.99) ug/l; respectively; $p = 0.05$. (Figure 2)

No significant difference in ADMA levelswas observed between ALL patients and the HC 0.60 (0.53; 0.66) umol/l; 0.58 (0.49; 0.61), respectively. (Figure 2)

No significant difference in VCAM plasma levels was observed between ALL patients and the HC: 941.7 (818.65; 1074.0) ug/l, 918.4 (793.08; 1017.90) ug/l; respectively. (Figure 2)

Discussion

Our study is the first to comprehensively evaluate ED in pediatric ALL survivors with respect to biochemical markers and RHI. Results of the study indicate that this combined approach may be used for the detection of ED in pediatric ALL survivors. There are several innovative findings in this study:1) significantly reduced RHI and2) elevated plasma levels of biochemical markersof ED when compared to healthy controls.

Several studies confirmed an increased cardiovascular risk in adult ALL survivors. The sequelae include predominantly well-documented components of metabolic syndrome with obesity, hypertension, insulin resistance and diabetes that increase cardiovascular risk (Alberti *et al.* 2006). Reported experience regarding ED and risk of cardiovascular diseases in young

ALL survivors is limited. Only two studies implicated ED as marker of early development of atherosclerosis in ALL survivors in childhood (Woo *et al* 2013) (Jarvela *et al.* 2013). Probandsin our study have a normal lipid profile and absence of metabolic syndrome (Table 1). Based on this fact,the association between treatment-related changes and ED seems to be plausible. Significantly elevated hsCRP level in children with ALL is in accordance with the proven relationship of hsCRP to atherogenic processes. Its elevated level is a predictive factor of morbidity and mortality from cardiovascular events in apparently healthy individuals, regardless of conventional risk factors(Wilson *et al.* 2008). One should respect that high plasmatic levels of hsCRP may be associated with acute inflammatory changes instead ED. Elevated E-selectin level reflectsendothelial activation. ADMA as a competitive NO-synthase inhibitor is related to increased oxidative stress and postocclusive vasodilation. The association of significantly elevated ADMA levels and ED was confirmed in our previous studies involving children with type 1 diabetes mellitus, familial hypercholesterolemia and Crohn's disease as well (Jehlicka *et al.* 2014) (Jehlicka *et al.* 2009). This relationship is supported by experimental studies confirming an intimate link among biochemical and functional endothelial changes (Mori-Kawabe *et al.* 2015). Surprisingly, we observed only slightly elevated ADMA plasma levels in ALL patients compared to healthy controls.

In respect to cardiovascular prevention, most of the published studies focused on cardiotoxicity of anthracyclines and related cardioprotection. Dexrazoxan, carvedilol or various alimentary supplements, such as L-carnitine, Coenzyme Q and others, were assessed in many studies that ultimately had ambiguous results(Jarvela *et al.* 2013) (Van Dalen *et al.* 2011). No valuable information regarding the effect of cardioprotective agents to endothelial functions in ALL survivors has been published to date. Only one study confirmed the positive effect of home-based exercise on endothelial function in children ALL survivors(Jarvela *et al.* 2013). From this point of view, further studies are highly needed.

From a technical aspect, many studies focused on ED used ultrasound methods, such as Flow Mediated Dilatation (FMD) or Intima Media Thickness (IMT). Reproducibility and accuracy of FMD are still matters of debate in children, mostly due to high dependency on operator's experience and demanding technical requirements (Al-Qaisi*et al.* 2008). IMT gradually increases during childhood, thus the precise cut-off values remain difficult to set in this population (Touboul *et al.* 2012). RHI, as a plethysmographic method, is technically easy to perform. Automatic analysis substantially reduces operator dependency and simultaneous measurement of the contralateral non-occluded arm allows for the elimination of unintended

exogenous changes during examination. The close relationship between decreased RHI and coronary dysfunctionwas confirmed via invasive methods (Selamet *et al.* 2009). Osika demonstrated a satisfactory variation coefficient of RHI and no sex differences in RHI score in a study including 248 school children (Osika *et al.* 2011).

Several limitations of the study merit consideration. One weakness of this study is the lack of a precise cut-off limit for RHI in children. Another limitation is that the sensors are unified and the minimum finger thickness is not defined. To avoid inaccurate results caused by measuring younger children with fingers too small for sensors, we only selected participants of age 12 and higher.Kelly demonstrated that younger age is associated with lower RHI but not lower FMD among children and adolescents and results of their study suggest that age is associated withRHI (Kelly *et al.* 2014).Therefore, we selected the control group with age comparable to ALL survivors. Hamburg demonstrated increased baseline pulse amplitude (PAT) in obese persons with metabolic syndrome and an inverse relationship between baseline and response PAT to hyperemia (Hamburg *et al.* 2008). Some studies did not find a correlation between FMD and RHI with respect to ED(Allan *et al.* 2013). This controversial finding might partly be explained by different properties of large conductive brachial arteries and the peripheral resistive artery bed. The precise underlying condition is still unclear and a definitive explanation still remains an area of research. There were published conflicting results regarding the ability of RHI to detect acute alterations of vasodilatation following smoking in a small study by Moerland(Moerland *et al.* 2012). However, smokers were not enrolled in the current sample.

Conclusions

PlethysmographicRHI and biochemical markers were used to assess ED in young ALL survivors in this study. Significantly decreased RHI, elevated plasma levels of hsCRP and E-selectin support a hypothesis of increased risk of premature ED in these patients. The combined approach seems to be a promising method for the assessment of endothelial

function. Further clinical ED investigations providing data for diagnostic and therapeutic applications are needed. To what extent it will influence the late cardiovascular risk remains to be answered by long-term studies.

Conflict of interests

The authors have no conflict of interests.

References

ALBERTI KG, ZIMMET P, SHAW J: Metabolic syndrome - A new world-wide definition.A consensus statement from the International Diabetes Federation. *Diabet Med.***23**: 469-480, 2006.

ALLAN RB, DELANEY CL, MILLER MD, SPARK JI: A comparison of flow-mediated dilatation and peripheral artery tonometry for measurment of endothelial function in healthy individuals and patents with peripheral artrial disease. *European Journal of Vasc***45**:263-269, 2013.

AL-QAISI M, KHARBANDA RK, MITTAL TK, DONALD AE: Measurment of endothelial function and its clinical utility for cardiovascular risk. *Vasc Health Risk Manag***4**: 647-652, 2008.

BARRY E, ALVAREZ JA, SCULLY RE, MILLER TL, LIPSHUTZ SE: Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. *Expert Opin Pharmacother***8:**1039-1058, 2007.

BHATIA S: Late effects among survivors of leukemia during childhood and adolescence. *Blood cells, Molecules, and Disease***31**: 84-92, 2003.

BONNETI PO, LERMAN LO, LERMAN A: Endothelial dysfunction – A marker of Atherosclerotic Risk. *Arterioscler Thromb Vasc Bio***23:** 168-175, 2003.

BOTTOMLEY SJ, KASSNER E. Late effects of childhood cancer therapy. *J Pediatr Nurs***18**:126-133, 2003.

BRYANT J, PICOT J, LEVITT G, SULLIVAN I, BAXTER L, CLEGG A: Cardioprotection against the toxic effects of anthracycline given to children with cancer: a systematic review. *Health Technol Assess***11**: 1- 84, 2007

DECARO E, SMERALDI A, TROCCHIO G, CALEVO M, HANAU G, PONGIGLIONE G: Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors. *Pediatr Blood Cancer***56**: 122-126, 2011.

ESSIG S, LI Q, CHEN Y: Risk of late effects of tratment in children with newly diagnosed with standard-risk acute lymphoblastic leukemia: a report from the childhood cancer Survivors Study cohort. [Online] Lancet Oncol, 2014. http://dx.doi.org/10.1016/S1470-2045(14)70265-7. published online June 2014.

GURNEY JG, SEVERSON RK, DAVIS S, ROBISON LL: Incidence of cancer in children in the United States. Sex-, race - , and 1-year age specific rates by histologic type. *Cancer* **75**: 2186-2195, 1995.

HAMBURG NM, KEYES MJ, LARSON MG, VASAN RS, SCHNABEL R, PRYDE MM, MITCHELL GF, SCHEFFY J, VITA JA, BENJAMIN EJ: Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. *Circulation***117**: 2467-2474, 2008.

HORNER MJ, RIES LAG, KRAPCHO M: Seer Cancer Statistics Rewiew, 1975-2006, Bethesda, MD: National Cancer Institute. [Online] 2009. http://ser.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission. posted to the SEER website, 2009.

JARVELA LS, NIINIKOSKI H, HEINONEN OJ, LAHTEENMAKI PM, AROLA M, KEMPPAINEN J: Endothelial function in long-term survivors of childhood acute lymphoblastic leukemia: effects of home-based exercise program. *Pediatr Blood Cancer***60:**1546-1551, 2013.

JEHLICKA P, HUML M, SCHWARZ J, TREFIL L, KOBR J, SYKORA J: Reactive hyperaemia index as a marker of endothelial dysfunction in children with Crohn´s disease is significantly lower than healthy controls. *Acta Pediatrica* **103**: 55 –60, 2014.

JEHLICKA P, STOZICKY F, MAYER O JR, VARVAROVSKA J, RACEK J, TREFIL L: Assymetric dimethylarginine and effects of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1 . *Physiol Res*. **58**: 179-84, 2009.

KADA-LOTTICK NS, ZELTZER LK, LIU Q, YASUI Y, ELLENBERG L, GIOIA G, ROBISON LL, KRULL KR: Neurocognitive functioning in adults survivors of childhood non-central nervous system cancers. *J Natl cancer Inst* **102**: 881-893, 2010.

KELLY AS, MARLATT AL, STEINBERGER L, DENGEL DR: Younger Age is Associated with Lower Reactive Hyperemic Index but not Lower Flow-Mediated Dilation among Children and Adolescents. *Atherosclerosis* **234(2)**: 410–414, 2014.

LEGER K, SLONE T, LEMLER M, LEONARD D, COCHRAN C, BOWMANPW, BASHORE L, WINICK N: Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. *Pediatr Blood cancer* **62**: 123-127, 2015.

MODY R, LI S, DOVER DC, SALLAN S, LEISENRING W, OEFFINGER KC, YASUI Y, ROBISON LL, NEGLIA JP: Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: report from the Childhood Survivor Study. *Blood* **111**: 5515-5523, 2008.

MOERLAND M, KALES AJ, SCHRIER L, VAN DONGEN MG, BRADNOCK D, BURGGRAAF J: Evaluation of the EndoPAT as a Tool to Assess Endothelial Function. *Int J Vasc Med* **2012**: 904141, 2012.

MORI-KAWABE M, YASUDA Y, ITO M, MATSUO S: Reduction of NO-mediated Relaxing Effects in the Thoracic Aorta in an Experimental Chronic Kidney Disease Mouse Model. *Atheroscler Thromb*2015 [Epub ahead of print].

MORISSON KM, DYAL L, CONNER W, HELDEN E, NEWKIRK L, YUSUF S, LONN E: Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. *Atherosclerosis***208**: 501-505, 2010.

NATHAN PC, WASILEWSKI-MASKER K, JANZEN LA: Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. *Hematology/Oncology Clinics of North America***5**: 1065-1082, 2005.

OEFFINGER KC, MERTENS AC, SKLAR CA, KAWASHIMA T, HUDSON MM, MEADOWS AT, FRIEDMAN DL, NEYSSA M, HOBBIE W, KADAN-LOTTICK NS, SCHWARTZ CL, LEISENRING W, ROBISON LL: Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med***355**:1572-1582, 2006.

OSIKA W, MONTGOMERY SM, DANGARDT F, WÄHRBORG P, GAN LM, TIDEMAN EA: Anger, depression and anxiety associated with endothelial function in childhood and adolescence. *Arch Dis Child***96**:38-43, 2011.

SELAMET TIERNEY ES, NEWBURGER JW, GAUVREAU K, GEVA J, COOGAN E, COLAN SD, DE FERRANTI SD: Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents.*J Pediatr***154**:901-905, 2009.

SILVERMAN LB. Balancing cure and long-term risk in acute lymphoblastic leukemia. *Hematology am Soc Hematol Educ Program***1**: 190-197, 2014.

TOUBOUL PJ, GROBBEE DE, DEN RUIJTER H: Assessment of subclinical atherosclerosis by carotid intima media thickness: technical issues. *Eur J Prev Cardiol***19**:18-24, 2012.

VAN DALEN EC, CARON HN, DICKINSON HO, KREMER LC: Cardioprotective interventions for cancer patients receiving anthracyclines. *Cochrane Database Syst Rev***15**:CD003917, 2011.

WIDLANSKY ME, GOKCE N, KEANEY JF JR, VITA JA: The clinical implications of endotehlial dysfunction. *J Am Coll Cardiol***42**: 1149-1160, 2003.

WILSON PWF, PENCINA M, JACQUES P, SELHUB J, D'AGOSTINO R, O'DONNELL CJ: C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. *Circ Cardiovasc Qual Outcomes***1**:92-97, 2008.

WOO JJ, DUK YC, IN-SANG J: Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia. *Korean J Pediatr***56(3)**: 130-134, 2013.

Data	ALL	Controls	P value
Subjects	22	18	
Gender (boys/girls)	15/7	5/13	
Age(years)	15.6 (12.72; 17.95)	16.1 (12.91; 17.33)	NS
BMI(kg/m2)	21.1 (19.3; 25.13)	19.97 (18.79; 22.85)	NS
Arterial blood pressure(mmHg)	116 (105; 121)/64 (60; 70)	114.5 (110;119)/62.5(59; 69.5)	NS
Reactive hyperemia index (RHI)	1.5(1.3; 2.0)	1.80 (1.59; 2.46)	p<0.05
E-selectin(ug/l)	76 (58.32; 108.98)	62.5 (31.66; 70.99)	p=0.05
ADMA (umol/l)	0.6 (0.53; 0.66)	0.58 (0.49; 0.61)	NS
hsCRP (mg/l)	1.1 (0.71; 2.29)	0.19 (0.18; 0.45)	p<0.001
VCAM(ug/l)	941.7 (818.66; 1074.0)	918.4 (793.08; 1017.90)	NS
Total Cholesterol (mmol/l)	4.2 (3.77; 4.67)	4.32 (3.93; 4.77)	NS

Legend table 1: values are expressed as median with inter-quartile range; ADMA – asymmetric dimethyl arginine; sVCAM – vascular cell adhesive molecule; hsCRP – high sensitive C-reactive protein; BMI – body mass index; ALL – acute lymphoblastic leukemia; NS – nonsignificant

Reactive hyperemia index (RHI)

Legend figure 1: Boxes indicate the inter-quartile range. Horizontal lines within boxes indicate medians. Whiskers extend to the highest or lowest values. 1. healthy controls; 2.acute lymphoblastic leukemia; p – *p*-value

Legend figure 2: Boxes indicate the inter-quartile range. Horizontal lines within boxes indicate medians. Whiskers extend to the highest or lowest values.1. healthy controls; 2.acute lymphoblastic leukemia; NS – non-significant difference; p – *p*-value